Following the outbreak of West Nile virus, which is transmitted by mosquitoes, in the US and in Portugal, buyers piled into vaccines developer Acambis. Shares of the company, which began Phase I trials of its West Nile vaccine in November, shot up to 350p and closed 17p better at 332 3/4p.